Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of postprandial hyperglycemia improvement on frailty and sarcopenia in older adults with type 2 diabetes
jRCTs051180050Completed
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Start
- Mar 2018
- Modality
- Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of voglibose, glimepiride and gliclazide in type 2 diabetes mellitus (T2DM), Fragility and Sarcopenia, sponsored by Kissei Pharmaceutical Co., Ltd. Primary endpoint: Frailty status and sarcopenia indices. Started Mar 2018; status: completed.
02
Drugs
vogliboseglimepiridegliclazide
03
Conditions
type 2 diabetes mellitus (T2DM)FragilitySarcopenia
Beyond the preview
Go deeper on jRCTs051180050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051180050.